This is a paid press release. Contact the press release distributor directly with any enquiries.
Innate Pharma Reports First Half 2026 Business Update and Financial Results
- IPHA
- AZN
- IPHA
-
New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027
-
€30 million equity financing completed to primarily support IPH4502 and preclinical ADC portfolio
-
IPH4502 Phase 1 dose escalation and cohort enrichment enrollment completed, with initial data to be presented at ENA 2026
-
PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026
-
Anticipated cash horizon until the end of Q1 2028, taking into account the initial payment of $75 million expected from the completion of the transaction with Sobi and the proceeds from the €30 million capital increase
-
Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET
MARSEILLE, France, September 17, 2026–(BUSINESS WIRE)–Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release.
“2026 continues to be an important year of execution for Innate, marked by our strategic partnership with Sobi and the strengthening of our financial position,”said Jonathan Dickinson, CEO of Innate Pharma.“With the TELLOMAK-3 Phase 3 study initiated, we are targeting the first patient in the study in Q1 2027 as we work toward a filing for accelerated approval in Sézary syndrome. Looking ahead, we will present Phase 1 data from IPH4502 at ENA 2026 and expect the PACIFIC-9 Phase 3 readout for monalizumab by year-end, as we remain focused on delivering value for patients and shareholders.”
|
1 Including short term investments (€4.4 million) and non-current financial instruments (€10.5 million) |
|
Webcast and conference call will be held today at 2:00pm CEST (8:00am ET) This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event. |
Lacutamab (anti-KIR3DL2 antibody), partnered with Sobi:
-
In August 2026, Innate Pharma entered into a strategic partnership with Sobi to license lacutamab in T-cell lymphoma (Link PR). The partnership is intended to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.
